Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;31(5):2021-8.
doi: 10.3892/or.2014.3106. Epub 2014 Mar 21.

MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma

Affiliations

MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma

Fei Guo et al. Oncol Rep. 2014 May.

Abstract

Ovarian carcinoma is the most lethal gynecologic malignancy; the majority of patients succumb to the disease within 5 years of diagnosis. The poor survival rate is attributed to diagnosis at advanced stage, when the tumor has metastasized. The epithelial-to-mesenchymal transition (EMT) is a necessary step toward metastatic tumor progression. Through integrated computational analysis, we recently identified a master microRNA (miRNA) network that includes miR-101 and regulates EMT in ovarian carcinoma. In the present study, we characterized the functions of miR-101. Using reporter gene assays, we demonstrated that miR-101 suppressed the expression of the E-cadherin repressors ZEB1 and ZEB2 by directly targeting the 3'-untranslated region (3'UTR) of both ZEB1 and ZEB2. Introduction of miR-101 significantly inhibited EMT and cell migration and invasion. Introducing cDNAs of ZEB1 and ZEB2 without 3'UTR abrogated miR-101-induced EMT alteration, respectively. Our findings showed that miR-101 represents a redundant mechanism for the miR-200 family that regulates EMT through two major E-cadherin transcriptional repressors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
miR-101 directly targets ZEB1 and ZEB2. (A) The two predicted miR-101-binding sites in the ZEB1 3′-UTR region are shown in the upper panel and the one predicted miR-101-binding site in the ZEB2 3′-UTR region is shown in the lower panel. (B) The pmirGLO-ZEB1 and pmirGLO-ZEB2 reporter genes had putative miR-101-binding sites cloned into the pmirGLO-control vector. The pmirGLO-ZEB1-mt vector had the two miR-101-binding sites deleted; the deletion was confirmed by sequencing. The pmirGLO-ZEB2-mt vector had the one miR-101-binding site deleted, and again the deletion was confirmed by sequencing. HeLa cells were transfected with pmirGLO-ZEB1 or pmirGLO-ZEB1-mt or with pmirGLO-ZEB2 or pmirGLO-ZEB2-mt, together with an miR-101 mimic or mimic negative control. The mean relative luciferase activities are shown, with standard errors, from 3 independent experiments.
Figure 2
Figure 2
miR-101 suppresses endogenous ZEB1 and ZEB2 expression. (A) ZEB1 and ZEB2 in SKOV3 cells were quantified by TaqMan real-time PCR. All data are means of triplicate PCR assays. (B) Levels of ZEB1 and ZEB2 proteins in SKOV3 cells transfected with miR-101 mimic (miR-101) or control (miR-Ctrl) were measured by western blotting using whole cell lysates from each sample.
Figure 3
Figure 3
miR-101 suppresses EMT and cell migration and invasion. (A) Levels of E-cadherin, fibronectin, N-cadherin and vimentin proteins in SKOV3 cells after transfection with miR-101 mimic (miR-101) or control (miR-Ctrl) were measured by western blotting using whole cell lysates from each sample. Actin was used to control protein loading. (B) Wound-healing assay was performed in SKOV3 cells. The extent of closure of the wound, representing cell migration, was monitored under phase-contrast microscopy and images were captured at 0 and 16 h. (C and D) Cell invasion assays in SKOV3 cells transfected with miR-101 or miR-Ctrl after 48 h. The cells were allowed to invade toward the lower chamber for 22 h. Each result in (D) represents an average of triplicates. (E) E-cadherin and F-actin immunofluorescence staining of SKOV3 cells transfected with miR-101 or miR101-Ctrl for 72 h. EMT, epithelial-to-mesenchymal transition.
Figure 4
Figure 4
ZEB1 and ZEB2 are EMT enhancers. (A and B) Levels of E-cadherin protein in SKOV3 cells after transfection with si-ZEB1, si-ZEB2, or siRNA-ctrl were measured by western blotting using whole cell lysates from each sample. Actin was used to control protein loading. (C) Wound-healing assay in SKOV3 cells after transfection with si-ZEB1, si-ZEB2, or si-ZEB1+2; the extent of closure of the wound, representing cell migration, was monitored under phase-contrast microscopy and images were captured at 0 and 16 h. EMT, epithelial-to-mesenchymal transition.
Figure 5
Figure 5
miR-101 suppresses EMT and increases E-cadherin expression independent of the miR-200 family. (A) Levels of E-cadherin (E-cad) and ZEB1 proteins in empty vector (EV) or ZEB1-overexpressing (C5 and C10, which are different clones) SKOV3 cells after transfection with miR-101 mimic (miR-101) or control (miR-Ctrl) were measured by western blotting using whole cell lysates from each sample. (B) Levels of E-cadherin and ZEB2 proteins in EV or ZEB2-overexpressing (C3 and C7, which are different clones) SKOV3 cells after transfection with miR-101 of miR-Ctrl were measured by western blotting using whole cell lysates from each sample. Actin was used to control protein loading. (C) Levels of miR-200a, miR-200c, and miR-141 in SKOV3 cells after miR-101 or miR-Ctrl transfection were analyzed by TaqMan miRNA quantitative PCR at 24, 48, 72 and 96 h. EMT, epithelial-to-mesenchymal transition.

Similar articles

Cited by

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
    1. Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2012;119(Suppl 2):S118–S129. - PubMed
    1. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110. - PubMed
    1. Arvizo RR, Saha S, Wang E, Robertson JD, Bhattacharya R, Mukherjee P. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci USA. 2013;110:6700–6705. - PMC - PubMed
    1. Gupta N, Xu Z, El-Sehemy A, Steed H, Fu Y. Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. Gynecol Oncol. 2013;130:200–206. - PubMed

Publication types

MeSH terms